# paper.pdf ## Metadata - PDFFormatVersion=1.7 - IsLinearized=false - IsAcroFormPresent=false - IsXFAPresent=false - IsCollectionPresent=false - IsSignaturesPresent=false - Producer=PDFlib+PDI 9.0.7p3 (C++/Win64) - CreationDate=D:20260611155357+05'30' - ModDate=D:20260611161617+05'30' - Title=SARS-CoV-2 reinfection: a possible contributing factor to long COVID in children and adolescents - Subject=child health, COVID-19, epidemiological factors, post-acute COVID-19 syndrome, post-infectious disorders, SARS-CoV2 - Keywords=child health; COVID-19; epidemiological factors; post-acute COVID-19 syndrome; post-infectious disorders; SARS-CoV2 - Creator=Rosela Lucero Chipol-Ceja, Jaime Morales-Romero, Carlos Alonso Rivero-López, María del Sagario Pérez-Callejas, Geovani López-Ortiz, Luis Del Carpio-Orantes, Claudia Iveth Spinoso-Torres, Santiago González-Periañez, María de Jesús Rodríguez-Cordoba, Liliana Ovando-Diego, Jorge Iván Zurutuza-Lorméndez - dc:creator=Rosela Lucero Chipol-Ceja,Jaime Morales-Romero,Carlos Alonso Rivero-López,María del Sagario Pérez-Callejas,Geovani López-Ortiz,Luis Del Carpio-Orantes,Claudia Iveth Spinoso-Torres,Santiago González-Periañez,María de Jesús Rodríguez-Cordoba,Liliana Ovando-Diego,Jorge Iván Zurutuza-Lorméndez - dc:description=Chipol-Ceja RL, Morales-Romero J, Rivero-López CA, Pérez-Callejas MS, López-Ortiz G, Del Carpio-Orantes L, Spinoso-Torres CI, González-Periañez S, Rodríguez-Cordoba María de Jesús, Ovando-Diego L and Zurutuza-Lorméndez Jorge Iván (2026) SARS-CoV-2 reinfection: a possible contributing factor to long COVID in children and adolescents. Front. Pediatr. 14:1691052. doi: 10.3389/fped.2026.1691052 - dc:format=application/pdf - dc:identifier=10.3389/fped.2026.1691052 - dc:rights=Copyright © 2026 Chipol-Ceja, Morales-Romero, Rivero-López, Pérez-Callejas, López-Ortiz, Del Carpio-Orantes, Spinoso-Torres, González-Periañez, Rodríguez-Cordoba, Ovando-Diego and Zurutuza-Lorméndez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. - dc:subject=child health,COVID-19,epidemiological factors,post-acute COVID-19 syndrome,post-infectious disorders,SARS-CoV2 - dc:title=SARS-CoV-2 reinfection: a possible contributing factor to long COVID in children and adolescents - pdf:keywords=child health; COVID-19; epidemiological factors; post-acute COVID-19 syndrome; post-infectious disorders; SARS-CoV2 - pdf:producer=PDFlib+PDI 9.0.7p3 (C++/Win64) - prism:aggregationtype=Journal - prism:doi=10.3389/fped.2026.1691052 - tiff:copyright=© 2026 Chipol-Ceja, Morales-Romero, Rivero-López, Pérez-Callejas, López-Ortiz, Del Carpio-Orantes, Spinoso-Torres, González-Periañez, Rodríguez-Cordoba, Ovando-Diego and Zurutuza-Lorméndez. - xmp:createdate=2026-06-11T15:53:57+05:30 - xmp:creatortool=Servigistics Arbortext Advanced Print Publisher 11.1.4546/W-x64 - xmp:metadatadate=2026-06-11T16:16:17+05:30 - xmp:modifydate=2026-06-11T16:16:17+05:30 - xmpmm:documentid=uuid:20b0125e-6863-11f1-0000-8a97f2137c15 - xmprights:marked=True - xmprights:webstatement=https://www.frontiersin.org/legal/copyright-statement ## Contents ### Page 1 EDITED BYDechuan Kong, Shanghai Municipal Center for Disease Control and Prevention (SCDC), ChinaREVIEWED BYPetar Velikov, National Centre of Infectious and Parasitic Diseases, Bulgaria Öykü Turunç, Koc University Faculty of Medicine, Türkiye*CORRESPONDENCEJorge Iván Zurutuza-Lorméndezjorzurutuza@uv.mxLiliana Ovando-Diegolovando@uv.mxRECEIVED 22 August 2025REVISED 08 May 2026ACCEPTED 13 May 2026PUBLISHED 16 June 2026CITATIONChipol-Ceja RL, Morales-Romero J, Rivero-López CA, Pérez-Callejas MS, López-Ortiz G, Del Carpio-Orantes L, Spinoso-Torres CI, González-Periañez S, Rodríguez-Cordoba MdJ, Ovando- Diego L and Zurutuza-Lorméndez JI (2026) SARS-CoV-2 reinfection: a possible contributing factor to long COVID in children and adolescents. Front. Pediatr. 14:1691052. doi: 10.3389/fped.2026.1691052COPYRIGHT© 2026 Chipol-Ceja, Morales-Romero, Rivero-López, Pérez-Callejas, López- Ortiz, Del Carpio-Orantes, Spinoso- Torres, González-Periañez, Rodríguez- Cordoba, Ovando-Diego and Zurutuza- Lorméndez. This is an open-access article distributed under the terms of theCreative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.SARS-CoV-2 reinfection: a possible contributing factor to long COVID in children and adolescentsRosela Lucero Chipol-Ceja1, Jaime Morales-Romero2, Carlos Alonso Rivero-López3, María del Sagario Pérez-Callejas4, Geovani López-Ortiz3, Luis Del Carpio-Orantes5, Claudia Iveth Spinoso-Torres6, Santiago González-Periañez7, María de Jesús Rodríguez-Cordoba8, Liliana Ovando-Diego8,9* and Jorge Iván Zurutuza-Lorméndez5*1Family Medicine Unit No. 34, Mexican Institute of Social Security, Catemaco, Mexico, 2Institute of Public Health, Universidad Veracruzana, Xalapa, Mexico, 3Division of Postgraduate Studies Family Medicine Subdivision, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico, 4Academic Secretary, Universidad Veracruzana, Xalapa, Veracruz, Mexico, 5Servicios de Salud de Veracruz, Xalapa, Mexico, 6Family Medicine Unit No. 36, Mexican Institute of Social Security, Cardel, Mexico, 7Faculty of Bioanalysis, Universidad Veracruzana, Xalapa, Mexico, 8Faculty of Medicine, Universidad Anáhuac Veracruz, Xalapa, Mexico, 9Family Medicine Unit No. 66, Mexican Institute of Social Security, Xalapa, MexicoBackground: Following the end of the COVID-19 pandemic, attention shifted towards patients who developed sequelae, persistent symptoms, or relapsing or remitting symptoms of new conditions after a prior history of acute SARS- CoV-2 infection. The objective of the present study was to identify the prevalence, clinical characteristics, and potential associated factors of long COVID in children treated during the pandemic in a primary care unit.Methods: A cross-sectional analytical study was conducted from January to December 2022. Children under 18 years of age and their parents were included in the study if they had been treated at the Mexican Social Security Institute. Two distinct manifestations of long COVID were considered: (a)“persistence”, defined as continuous symptoms beginning in the acute phase and lasting for more than 3 months; and (b) “post-COVID conditions”, defined as new or recurrent symptoms lasting for more than 3 months, appearing after the acute episode, and not associated with any active disease or infectious condition. An exploratory binary logistic regression analysis was performed to identify associated factors, using an odds ratio (OR) as the measure of association.Results: The study included 349 children and adolescents. The prevalence of long COVID was 11.8% (95%CI 7.8%–17.5%). For “persistence”, the most frequent symptoms were cough (50%) and rhinorrhea (15.4%); for “post- COVID conditions”, the most common symptoms were myalgia (33.3%), asthenia and irritability (26.7% each), and constipation (20%). Multivariate analysis revealed that the associated factors for individuals aged over 8 years were a history of reinfection (OR 9.7, 95%CI 1.6–58) and BMI at the time of the survey (OR 1.1, 95%CI 1.0–1.2), while for those aged under 8 years, the associated factor was male sex (OR 4.7, 95%CI 1.3–17.3). It is important to emphasize that these results are the product of an exploratory analysis and aim to create and test new hypotheses.TYPE Original ResearchPUBLISHED 16 June 2026DOI 10.3389/fped.2026.1691052Frontiers in Pediatrics 01 frontiersin.org ### Page 2 Conclusions: For healthcare professionals, it is crucial to consider the possibility of long COVID, as this study indicated that approximately 12% of children and adolescents may be affected. Further research is necessary to better understand and manage long COVID in pediatric populations and to investigate the association between reinfections and their increased prevalence.KEYWORDSchild health, COVID-19, epidemiological factors, post-acute COVID-19 syndrome, post- infectious disorders, SARS-CoV21 IntroductionFollowing the declaration of the end of the COVID-19 pandemic caused by SARS-CoV-2 on 5 May 2023 by the World Health Organization (WHO), scientific research groups have begun focusing on evaluating the sequelae of the disease, along with the persistence of symptoms or the emergence of new symptoms without an apparent cause in individuals with a prior history of COVID-19 (1, 2). This new chronic manifestation of the disease initially lacked a clear definition or name, but it was identified almost concurrently with the progression of the pandemic, with reports of its emergence dating back to 2020 and attributing its occurrence to disease sequelae and relapses (3–5).This variability in clinical recognition has complicated diagnosis, resulting in reported prevalences ranging from 2.6% to 93.3%. This range has been attributed to differences in disease severity, age, vaccination status, and a variety of other factors, with an average prevalence of approximately 42.1% in the general population (6). In 2024, the National Academies of Sciences, Engineering, and Medicine (NASEM) in the United States proposed a comprehensive definition of long COVID, integrating multiple perspectives and specifying that: “There must be a diagnosis of COVID-19 prior to the onset of symptoms, regardless of the severity of the acute condition; symptoms must persist for a minimum duration of three months, with onset during the acute phase or later, presenting as continuous, recurrent, remitting, or progressive, and affecting one or more organs" (7) [SIC].In children, this issue has proven to be significantly more complex due to the higher proportion of asymptomatic cases during the acute phase in this population. Reported prevalence ranges from 1.06% to 70% (8), with approximately 4% considered the general average (9). Those most affected include those who required hospitalization, experienced severe disease, or were unvaccinated (i.e., had not received at least one dose at the time of the acute episode) (8–10). Several studies have described the clinical characteristics and risk factors of long COVID in children, with the most frequent symptoms including fatigue, myalgia, headache, anosmia, dysgeusia, cough, facial paralysis, hoarseness/dysphonia, acute hearing loss, tinnitus, vertigo/dizziness, anxiety, and depression (11–14). This condition represents an economic burden due to the need for continuous and long-term care, in addition to having a significant impact on quality of life (15, 16).The majority of studies on long COVID in children are based on population cohorts from the United States (10–12, 15–17). However, studies conducted on different cohorts in other countries have identified varying prevalences, clinical characteristics, and risk factors (8, 9, 13, 14), making population-specific research essential. In Mexico, studies have primarily focused on the adult population (18), while those involving pediatric patients have mainly addressed acute disease and vaccination in this age group (19). Evidence regarding pediatric long COVID in primary care settings in Mexico remains scarce. This hinders timely case recognition, increases the risk of underdiagnosis, and limits the development of diagnostic, follow-up, and treatment strategies adapted to the local context and healthcare system.In this context, the objective of this study was to identify the prevalence, clinical characteristics, and potential associated factors of long COVID in children with symptomatic acute illness who were treated during the pandemic in a primary care unit.2 Materials and methods2.1 Study populationA cross-sectional analytical study was conducted from January to December 2022. The included patients were invited to the waiting area of a Family Medicine unit of the Mexican Social Security Institute, a primary care facility located in Xalapa, Veracruz (Mexico), where they were interviewed. Data used to identify and locate the patients were obtained from the unit’s epidemiological surveillance records, which documented the use of diagnostic tests. The inclusion criteria comprised children and adolescents under 18 years of age with symptomatic COVID-19 confirmed by rapid antigen testing or polymerase chain reaction (PCR), whose parents participated as respondents.Two distinct manifestations of long COVID were considered: (a) “persistence”, defined as continuous symptoms beginning in the acute phase and lasting for more than 3 months; and (b) “post-COVID conditions”, defined as new or recurrent symptoms lasting for more than 3 months, appearing after the acute episode, and not associated with any active disease or infectious condition. Regarding the latter criterion, a complete medical evaluation of the child was carried out by a trained physician to detect infectious conditions or diseases causing the reported symptoms; if necessary, complementary laboratory or imaging tests were performed.The occurrence of a subsequent acute episode was evaluated using PCR, with the results obtained retrospectively from the epidemiological surveillance records; only cases with a positive result were considered to be SARS-CoV-2 reinfections, in which case the 3-month evaluation period was restarted.Chipol-Ceja et al. 10.3389/fped.2026.1691052Frontiers in Pediatrics 02 frontiersin.org ### Page 3 The exclusion criteria included cognitive, intellectual, or hearing impairments in parents, preventing completion of the questionnaire. At the time of the study, COVID-19 vaccination had not yet been approved for children in Mexico; therefore, none of the participants had been vaccinated (the vaccination period for children over 12 years old began at the end of 2022 in Mexico). Furthermore, the study population corresponded to a primary outpatient care setting, as defined by national healthcare protocols during the health emergency; patients with severe disease were referred to specialized hospitals. All patients who met the selection criteria and whose parents provided informed consent were included. This process is illustrated in Figure 1.2.2 Data collection and processingA structured questionnaire was used to record the following: age at COVID-19 diagnosis (acute phase); sex; weight, height, and body mass index (BMI). In addition, a clinical interview was conducted to identify signs and symptoms associated with long COVID in children, including their presence and duration. The symptoms assessed included fever, myalgia, arthralgia, headache, cough, anosmia, ageusia, rhinorrhea, dyspnea or shortness of breath, diarrhea, fatigue, sore throat, hyporexia (loss of appetite), asthenia, vertigo/dizziness, constipation, and parental perceptions of irritability, confusion, memory loss, anxiety, and depression. Family type (20) and Geyman’s family life cycle phase (21) were also recorded.Clinical interviews were the primary method used to identify symptoms and were conducted by a primary care physician, who inquired about the presence of the listed symptoms. The selection of the investigated signs and symptoms was guided by parent- reported instruments, following the methodology proposed by Asadi-Pooya et al. (22). In addition, medical records were reviewed, and for children aged over 8 years, the child was also interviewed to supplement and confirm parental reports.A descriptive analysis was performed using summary statistics and measures of central tendency. For the comparison of categorical variables, the chi-square test with Mantel–Haenszel correction or Fisher’s exact test was used; for continuous variables, a Student’s t-test or the Mann–Whitney U-test was employed. An exploratory block binary logistic regression analysis (enter method) was used to identify associated factors through odds ratios (ORs), with the presence or absence of long COVID (including both “persistence” and “post-COVID conditions”) considered the dependent variable in all models.The independent variables were entered as a block in the following order: SARS-CoV-2 reinfection, time elapsed since the acute episode, BMI, sex, and finally, age. Based on these results, significant, borderline significant, and potentially confounding variables were used to construct four multivariable models in the study sample, which was stratified into two groups according to patient age: ≥ 8 years and < 8 years. This stratification was applied because children aged ≥ 8 years were able to respond to questions about their illness, whereas children aged < 8 years relied solely on parental reports. Model I included only the variable “SARS-CoV-2 reinfection” (unadjusted); additional variables were introduced sequentially until the final Model IV (fully adjusted) was obtained. Independent variables demonstrating collinearity, defined as a variance inflation factor (VIF) > 5, were excluded. Model fit was assessed using the Hosmer–Lemeshow test (p > 0.05). The MID-P method was used to calculate confidence intervals for prevalence estimates. All analyses were performed using IBM SPSS Statistics for Mac, version 29.0.2.3 Ethical approvalThe study protocol was approved by the Research Committee and the Research Ethics Committee of the Mexican Social Security Institute (registration number R-2023-3007-047). All parents were informed about the purpose of the study and provided informed consent. In addition, all children aged over 8 years were asked to provide assent, as their parents were supplying personal information on their behalf.3 Results3.1 Population characteristicsThe study included 349 children and adolescents (response rate: 92.3%). The general characteristics of the study population are summarized in Table 1. Age at diagnosis ranged from 10 months to 18 years, with a median of 12 years [interquartile range (IQR): 6 years]. The male sex, at 51.9% of the sample, comprised the majority of participants. Regarding family characteristics, the majority of children belonged to simple nuclear families (80.5%); 98.9% of the families resided in urban areas, 66.5% were classified as modern families, and 64.2% were engaged in the services sector. The above refers to the father with the greatest share in the family income.3.2 Prevalence and symptoms of long COVIDThe prevalence of long COVID was estimated at 11.8% [95% confidence interval (95%CI): 7.8%–17.5%], with 7.5% (95%CI: 5.2%–10.6%) corresponding to “persistence” and 4.3% (95%CI: 2.6%–6.9%) to “post-COVID conditions” (Figure 2). A total of 2.5% (9 cases) had a history of reinfection following the acute episode. Symptoms observed during the acute phase and in long COVID cases are presented in Tables 2, 3, respectively. The most prevalent symptoms during the acute phase were fever (69.3%), headache (69.6%), rhinorrhea (64.5%), cough (63.3%), odynophagia (55.6%), and myalgia (50.7%). In “persistence” cases, the most frequent symptoms were cough (50%) and rhinorrhea (15.4%). In contrast, in “post-COVID conditions”, the most common symptoms were myalgia (33.3%), asthenia and irritability (26.7% each), and constipation (20%).3.3 Factors associated with long COVIDTable 4 presents factors associated with long COVID that increased its probability, including male sex and a shorter time since the acute episode (< 1 year). Factors associated with a reduced probability included older age at the time of acute illness, a higher BMI at the time of the survey, and more timeChipol-Ceja et al. 10.3389/fped.2026.1691052Frontiers in Pediatrics 03 frontiersin.org ### Page 4 elapsed since the acute episode. All these associations had p-values < 0.05. No variables were significantly associated with the subdivision between “persistence” and “post-COVID conditions” (see Supplementary Material Table S4).Two binary logistic regression models were constructed according to patient age (≥ 8 years and < 8 years), based on the child’s ability to contribute to symptom reporting. In children aged ≥ 8 years, the associated factors included a history of reinfection (OR 9.7, 95%CI: 1.6–58) and BMI at the time of the survey (OR 1.1, 95%CI: 1.0–1.2). In children aged < 8 years, the associated factor was male sex (OR 4.7, 95%CI: 1.3–17.3). The full set of models is presented in Table 5.4 DiscussionIn Mexico, there is limited data on the prevalence of long COVID in children and adolescents, as the National Health andFIGURE 1General flowchart of the study design. Created in BioRender, available at: https://BioRender.com/vfxjoavChipol-Ceja et al. 10.3389/fped.2026.1691052Frontiers in Pediatrics 04 frontiersin.org ### Page 5 Nutrition Survey (ENSANUT), responsible for generating official national statistics, has focused primarily on adults (18, 23). The study with the largest pediatric population in Mexico is that described by Martínez-Valdez et al. (19); however, it was limited to describing the acute phase of the disease, without identifying patients who continued to experience symptoms or sequelae.One of the most significant challenges is the definitive diagnosis of long COVID. Despite the existence of an established definition (7), the possibility that symptoms are attributable to other diseases or are coincidental continues to obscure accurate case identification. One proposed method to improve diagnostic accuracy is the establishment of a clinicalTABLE 1 General characteristics of the study population (n = 349).Variable Summary StatisticDispersionMen 181 51.9Women 168 48.1Age group at the time of acute COVID-19 infection (n, %)Less than 2 years old 15 4.32–5 years old 22 6.3Over 5 years old 312 89.4Body mass index at the time of the survey by age group (P50, P75− P25)>1 year old 21.5 19.2,291 year old 16.1 14.6,20.12–4 years old 16.5 15.6,185–9 years old 18.6 16.2,21.510–14 years old 21.5 18.5,23.615–18 years old 23.3 21.5,25.6Body mass index at the time of the survey (overall) (P50, P75 − P25)21.4 17.9,23.8Time elapsed since the acute episode (n, %)3–6 months 4 1.2>6–12 months 95 27.2>12–24 months 246 70.5>24 months 4 1.1Family classification based on kinship (n, %)Simple nuclear 281 80.5Numerous nuclear 14 4.0Reconstructed 1 0.3Single-parent 51 14.6Extended single-parent 1 0.3Extensive compound 1 0.3Family classification based on physical presence in the home(n, %)Integrated core 280 80.2Non-integrated core 68 19.5Extensive ascending 1 0.3Family classification based on its demographics (n, %)Urban 345 98.9Rural 4 1.1Family classification based on its development (n, %)Traditional 117 33.5Modern 232 66.5Family classification based on occupation (n, %)Industrial 34 9.7Commercial 91 26.1Services 224 64.2(Continued)TABLE 1 ContinuedVariable Summary StatisticDispersionClassified BMIa at the time of the surveyLow weight 12 3.4Suitable weight 214 61.3Overweight 67 19.2Obesity 56 16.1Presence or absence of long COVID (n, %)Presence of long COVID 41 11.8Absence of long COVID 308 88.3Presence or absence of long COVID (subclassified into “post- COVID conditions” and “persistence” groups) (n, %)No long COVID 308 88.3Long COVID (post-COVID conditions)15 4.4Long COVID (Persistence) 26 7.5Long COVID (Persistence and/or post-COVID conditions)41 11.8SARS-CoV-2 reinfection (n, %)No 340 97.4Yes 9 2.6Weight at the time of the survey (Kilograms) (P50, P25 - P75)48 31,60Height at the time of the survey (Meters) (P50, P25 - P75)1.5 1.3,1.6Age at the time of acute COVID- 19 (P50, P25 - P75)12 9,15Number of signs or symptoms in those in the persistence group (P50, P25 - P75)1 1,1Number of signs or symptoms in those in the post-COVID conditions group (P50, P25 - P75)1 1,2NC not calculable, P50: median, P25: 25th percentile, P75: 75th percentile. BMI: Body mass index (kg/m2). NA: Not applicable.aTo classify BMI at the time of the survey, the WHO z-score was used according to the following divisions: for children under 2 years of age, weight-for-length was used; for children aged 2–5 years, weight-for-height was used; and for children over 5 years, BMI tables were used.Chipol-Ceja et al. 10.3389/fped.2026.1691052Frontiers in Pediatrics 05 frontiersin.org ### Page 6 “threshold” based on data from the RECOVER Pediatric Observational Cohort Study (RECOVER-Pediatrics) (17, 24). This threshold facilitates clearer case identification; that study has reported that the prevalence of at least one persistent symptom may increase long COVID prevalence to 45% in children (ages 5–12) and 39% in adolescents (ages 12–18) with a positive test result (17). When applying this threshold, the prevalence rates decrease to 20% in children and 4% in adolescents (17). These findings align more closely with those of the present study, which identified a prevalence of 11.8% (95%CI 7.8%–17.5%) even without applying a threshold, with higher prevalence rates observed in younger patients at diagnosis. This consistency supports the plausibility of our findings.A key finding of the present study was the prevalence of 11.8% (95%CI 7.8%–17.5%) in children and adolescents without prior vaccination following a symptomatic acute episode. Comparison with other studies is challenging due to differences in selection criteria. When standardizing for symptomatic cases with at least 3 months of follow-up, however, our findings can be compared with the 4.8% prevalence reported in the German study “COVID-19/SARS-CoV-2 seroconversion in children” (CorKid) (10, 25), which focused on the Omicron variant. For earlier variants, a prevalence of 14.2% has been reported (10, 25). It is important to note that the comparative study had a smaller sample size than ours. Cough and dyspnea were frequent respiratory symptoms, consistent with our findings; cough was more prevalent in the “persistence” group than in the “post- COVID conditions” group (50% vs. 13.3%). Differences in prevalence may be explained by variations in follow-up duration, severity of acute illness, age, and SARS-CoV-2 variants. Unfortunately, stratification by viral strain was not possible in our study, as only a small proportion of PCR-positive cases were subtyped in Mexico.Another relevant finding of the present study was the association between male sex and increased probability of long COVID in children under 8 years of age (OR 4.7, 95%CI: 1.3–17.3). This is consistent with findings in adult populations, where this effect has been linked to hormonal, immunological, and receptor expression factors (26).A systematic review of 349 children and adolescents reported a global prevalence of long COVID of 25.24%, with the most frequent symptoms including mood disturbances (sadness, tension, anger, depression, anxiety) in 16.5% of the subjects, fatigue in 9.62% of the subjects, sleep disorders in 8.42% of the subjects, headaches in 7.84% of the subjects, and respiratory symptoms in 7.62% of the subjects. Comparison was complicated by variation in follow-up duration, which ranges from 4 to 12 weeks or longer (27). This may explain the lower prevalence observed in our study. These variations highlight the importance of studying different populations and contexts.The instrument proposed by Asadi-Pooya et al. (22) is among the simplest and most effective tools for identifying long COVID in pediatric populations. Using this instrument, a prevalence of 44.8% was reported in that study, with the most frequent symptoms being fatigue (21%), shortness of breath (12%), cough (7%), muscle and joint pain (5%), and headache (5%). These findings differ from ours, where objective symptoms such as cough and rhinorrhea were more prevalent. This discrepancy may be explained by reliance on parent-reported data. Although the data collection methods were similar, our study incorporated both parental and child reports where possible, depending on the child’s age.Regarding symptom prevalence, the review by Pellegrino et al. (8) identified fatigue, headache, muscle and joint pain, chest pain, dyspnea, and alterations in the sense of taste or smell as the most frequent symptoms. In our study, only headache was identified as a high-frequency symptom. Similarly, Basaca et al. (9) reported headache prevalence ranging from 3% to 80%, along with dizziness and memory loss, both of which were relatively uncommon in our sample (3.9%–6.7%).A systematic review in otorhinolaryngology (12) identified cough as a frequent symptom (4%–19%), along with anosmia (14% at 60 days) and dysgeusia (12% at 60 days), both of which were more common than in our findings. It is noteworthy that symptoms tend to decrease over time, a pattern also observed in our study: one year was sufficient for a significant reduction in long COVID cases.Vaccination has been shown to not only reduce the incidence of acute symptomatic disease and severe forms but also to decrease the likelihood of developing long COVID (28). However, due to delays in vaccine availability, none of the study participants had been vaccinated at the time of the study (29).FIGURE 2Prevalence of long COVID in children and adolescents. A) Long COVID (Persistence or/and post-COVID conditions groups included). B) Long COVID (persistence group only). C) Long COVID (post-COVID conditions group only). Created in GraphPad Prism 11.0.2.Chipol-Ceja et al. 10.3389/fped.2026.1691052Frontiers in Pediatrics 06 frontiersin.org ### Page 7 The long-term effects of long COVID in children and adolescents remain uncertain. These may range from measurable outcomes, such as increased mortality (30), to broader impacts such as rising healthcare costs (16), reduced physical activity in children and adolescents (15), and widening social and economic inequalities (31). This underscores the need for continued research, improved diagnostic tools, and the development of targeted care programs.Regression analysis of children aged ≥ 8 years identified reinfection as a factor associated with an increased probability of long COVID (OR 9.7, 95%CI: 1.6–58). This is consistent with findings in adult populations, where the risk of long COVID increases with each reinfection (32), particularly when the intervals between infections are shorter (33). However, it is important to mention that the number of confirmed reinfections for each analyzed group is small: 7 forTABLE 2 Prevalence of signs and symptoms in subjects with acute COVID-19.Symptom Acute COVID-19n = 349n %HeadacheNo 106 30.4Yes 243 69.6FeverNo 107 30.7Yes 242 69.3RhinorrheaNo 124 35.5Yes 225 64.5CoughNo 128 36.7Yes 221 63.3Sore throatNo 155 44.4Yes 194 55.6MyalgiaNo 172 49.3Yes 177 50.7ArthralgiaNo 181 51.9Yes 168 48.1AstheniaNo 226 64.8Yes 123 35.2FatigueNo 234 67Yes 115 33AnosmiaNo 249 71.4Yes 100 28.7AgeusiaNo 265 75.9Yes 84 24.1Only the 11 most relevant signs or symptoms in patients with acute COVID-19 were included; the complete table can be found in the Supplementary Material.TABLE 3 Prevalence of signs and symptoms in long COVID (divided into “persistence” and“post-COVID conditions” groups).Symptom Long COVIDPersistence Post-COVID conditions(n = 26) % (n = 15) %ArthralgiaNo 26 100.00 13 86.7Yes 0 0.00 2 13.3MyalgiaNo 26 100.00 10 66.7Yes 0 0.00 5 33.3Dyspnea or shortness of breathNo 25 96.1 15 100.0Yes 1 3.9 0 0.0CoughNo 13 50.0 13 86.7Yes 13 50.0 2 13.3DiarrheaNo 24 92.3 13 86.7Yes 2 7.7 2 13.3AgeusiaNo 24 92.3 14 93.3Yes 2 7.7 1 6.7RhinorrheaNo 22 84.6 14 93.3Yes 4 15.4 1 6.7AstheniaNo 25 96.1 11 73.3Yes 1 3.9 4 26.7IrritabilityNo 24 92.3 11 73.3Yes 2 7.7 4 26.7AnxietyNo 25 96.1 13 86.7Yes 1 3.9 2 13.3Only the 10 most relevant signs or symptoms in patients in the persistence or post-COVID conditions groups were included; the complete table can be found in the Supplementary Material.Chipol-Ceja et al. 10.3389/fped.2026.1691052Frontiers in Pediatrics 07 frontiersin.org ### Page 8 the group over 8 years old and 2 for the group under 8 years old, so the results should be interpreted with caution. It is necessary to continue investigating the effect of reinfection confirmed by viral identification on the prevalence of long COVID.This study has several limitations, including its cross-sectional design, which precludes causal inference, potential recall bias, and a relatively limited sample size. Additionally, asymptomatic cases were excluded due to healthcare protocols during the pandemic, which prioritized testing for symptomatic individuals. Parent-TABLE 4 Univariate analysis of factors associated with long COVID in children and adolescents.Variables Categories Without long COVID (n = 308)With long COVID (n = 41)p-value OR (CI)95% (Not adjusted)n % n %Sex Male 153 49.7 28 68.3 0.03ª 2.2* (1.1–4.4)Female 155 50.3 13 31.7SARS-CoV-2 reinfection No 302 98.1 38 92.7 0.07b 3.9 (0.95–16.5)Yes 6 2.0 3 7.3Time elapsed since the acute episode < 1 year 73 23.7 26 63.4 <0.01a* 5.6* (2.8–11.1)1 year or more 235 76.3 15 36.6Classified BMIe (at the time of the survey) Adequate weight 193 62.7 21 51.2 0.16c 1.6 (0.8–3.1)Underweight or overweight 115 37.3 20 48.8Variables P50 p25,p75 P50 p25,p75 p-value OR (CI)95% (Not adjusted)Age at acute illness (older age) 13 10,16 7 1.8,11 <0.01d* 0.78* (0.72–0.84)BMI at the time of the survey (higher) 21.6 18.3,24 18.3 16.4,21.5 <0.01d* 0.86* (0.78–0.94)Time elapsed since the acute episode (in months) 451 384,555 313 252, 437 <0.01d* 0.79* (0.73–0.87)Statistical tests used: aPearson Chi-square, bFisher Exact Test, cMantel-Haenzel correction for Chi-square, dU Mann–Whitney test.NC not calculable, Me median, P25: 25th percentile, P50: 50th percentile, P75: 75th percentile. BMI: Body mass index (kg/m2). NA: Not applicable.eTo classify BMI, the WHO z-score was used according to the following divisions: for children under 2 years of age, weight-for-length was used; for children aged 2 to 5 years, weight- forheight was used; and for children over 5 years, BMI tables were used.*Statistical significance, p-value <0.05TABLE 5 Exploratory multivariate analysis of factors associated in children with long COVID, defined as persistence (continuous) and post-COVID conditions (new or recurrent).Variable Model I Model II Model III Modelo IVOR (IC95%) p OR (IC95%) p OR (IC95%) p OR (IC95%) pChildren aged ≥ 8 years (n = 281)SARS-CoV-2 reinfection 6.9 (1.2–38.6) 0.028 8.7 (1.5–52.1) 0.017 9.2 (1.5–54.7) 0.015 9.7 (1.6–58.0) 0.013Time elapsed since the acute episode (in months) 0.8 (0.7–0.9) 0.001 0.8 (0.7–0.9) <0.001 0.8 (0.6–1.0) 0.053BMI (Kg/m2) 1.1 (0.95 to 1.2) 0.278 1.1 (1.0–1.2) 0.249Sex (men) 0.7 (0.3–2.1) 0.572Age (years) 0.9 (0.7–1.3) 0.648Children aged < 8 years (n = 68)SARS-CoV-2 reinfection 1.9 (0.1–31.3) 0.663 1.7 (0.1–30.0) 0.705 2.0 (0.1–36.4) 0.636 2.0 (0.1–43.2) 0.658Time elapsed since the acute episode (in months) 1.0 (0.9–1.2) 0.723 1.04 (0.9–1.2) 0.866 1.0 (0.8–1.2) 0.946BMI (Kg/m2) 0.9 (0.7–1.0) 0.134 0.9 (0.7–1.1) 0.184Sex (men) 4.7 (1.3–17.3) 0.020Age (years) 0.9 (0.7–1.1) 0.340Exploratory multivariable logistic regression models.Time elapsed from the acute phase of COVID-19 to the day of the interview.BMI, Body mass index at the time of the survey.Age at diagnosis of COVID-19.Number of reinfections per group: 2 in children under 8 years old and 7 in children over 8 years old.OR, Odds ratio obtained through binary logistic regression.Variables introduced using the “Enter”method.Chipol-Ceja et al. 10.3389/fped.2026.1691052Frontiers in Pediatrics 08 frontiersin.org ### Page 9 reported data may overemphasize observable symptoms (e.g., cough) while underrecognizing subjective symptoms, such as fatigue or cognitive changes, particularly in younger children. The inclusion of children aged ≥ 8 years was therefore essential to capture subjective symptoms. The small sample size in the subgroup of children < 8 years may also have introduced a type II error. Furthermore, the small number of reinfections reduced precision, as reflected in wide confidence intervals. An important limitation is the small number of children under 2 years of age (15 children, 4.3%) and those aged 3–5 years (22 children, 6.3%). This may reflect a higher proportion of asymptomatic cases in these age groups and the difficulty parents face in recognizing symptoms, as these children rely on third-party identification and reporting. Finally, because reinfection was observed in only nine participants, the association estimates are imprecise and should not be interpreted as confirmatory.The strengths of this study include: (1) strict selection criteria; (2) confirmation of SARS-CoV-2 infection in all participants; (3) use of a contemporary definition of long COVID (7); and (4) a high response rate, reflecting a population engaged with healthcare research.5 ConclusionLong COVID remains a relevant and complex condition that requires continued attention, including in children and adolescents. This study identified a prevalence of 11.8% (95%CI 7.8%–17.5%) among unvaccinated symptomatic patients treated in primary care, underscoring the need for greater clinical awareness in routine practice.Failure to recognize long COVID may lead to misdiagnosis and suboptimal treatment. Identifying factors associated with each age group, such as sex and a history of reinfection, may help prioritize monitoring and care for vulnerable groups. It is important to remember that this article serves as a hypothesis generator that requires subsequent research to confirm the findings. Further research is needed to standardize diagnostic criteria, assess long-term outcomes, and develop evidence-based treatment strategies in pediatric populations, particularly in settings with limited existing data, such as Mexico.Data availability statementThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.Ethics statementThe studies involving humans were approved by Research Committee and the Research Ethics Committee of the Mexican Social Security Institute (registration number R-2023-3007-047). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin. Informed assent was also requested from children aged 8 and older to participate in the study.Author contributionsRC-C: Writing – original draft, Conceptualization, Investigation. JM-R: Formal analysis, Data curation, Writing –review & editing. CR-L: Writing – review & editing. MP-C: Formal analysis, Data curation, Writing – review & editing. GL- O: Writing – review & editing. LC-O: Writing – review & editing. CS-T: Writing – review & editing. SG-P: Writing –review & editing, Visualization. MR-C: Writing – review & editing. LO-D: Supervision, Conceptualization, Investigation, Writing – original draft, Project administration. JZ-L: Supervision, Investigation, Conceptualization, Software, Formal analysis, Writing – original draft, Methodology, Data curation.FundingThe author(s) declared that financial support was not received for this work and/or its publication.Conflict of interestThe author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Generative AI statementThe author(s) declared that generative AI was not used in the creation of this manuscript.Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.Publisher’s noteAll claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary materialThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2026. 1691052/full#supplementary-materialChipol-Ceja et al. 10.3389/fped.2026.1691052Frontiers in Pediatrics 09 frontiersin.org ### Page 10 References1. United, Nations. The head of the WHO declares the end of COVID-19 as a global health emergency. (2023). Available online at: https://news.un.org/en/story/2023/05/ 1136367 (Accessed March 25, 2026)2. WHO. Post-COVID-19 (Long COVID) condition. (2022). Available online at:https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition(Accessed March 25, 2025).3. Alwan NA, Johnson L. Defining long COVID: going back to the start. Med. (2021) 2(5):501–4. doi: 10.1016/j.medj.2021.03.0034. Halpin S, O’Connor R, Sivan M. Long COVID and chronic COVID syndromes.J Med Virol. (2021) 93(3):1242–3. doi: 10.1002/jmv.265875. Sivan M, Taylor S. NICE Guideline on long COVID. Br Med J. (2020) 371:m4938.doi: 10.1136/bmj.m49386. Woodrow M, Carey C, Ziauddeen N, Thomas R, Akrami A, Lutje V, et al. Systematic review of the prevalence of long COVID. Open Forum Infect Dis. (2023) 10(7):ofad233. doi: 10.1093/ofid/ofad2337. National Academies of Sciences E, Medicine. A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. Fineberg HV, Brown L, Worku T, Goldowitz I, editor. Washington, DC: The National Academies Press (2024). p. 186.8. Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and clinical presentation of long COVID in children: a systematic review. Eur J Pediatr. (2022) 181(12):3995–4009. doi: 10.1007/s00431-022-04600-x9. Basaca DG, Juganaru I, Belei O, Nicoara DM, Asproniu R, Stoicescu ER, et al. Long COVID in children and adolescents: mechanisms, symptoms, and long-term impact on health-A comprehensive review. J Clin Med. (2025) 14(2): 1–20. doi: 10.3390/ jcm1402037810. Hoppner J, Maier C, Schlegtendal A, Hoffmann A, Petersmann A, Lucke T, et al. Long-term effects of SARS-CoV-2 infection and vaccination in a population-based pediatric cohort. Sci Rep. (2025) 15(1):2921. doi: 10.1038/s41598-024-84140-611. Gupte A, Sriram S, Gunasekaran V, Chaudhari K, Kamat D. The triad of COVID- 19 in children: acute COVID-19, multisystem inflammatory syndrome, and long COVID-part II. Pediatr Ann. (2025) 54(1):e40–e4. doi: 10.3928/19382359- 20241106-0112. Guntinas-Lichius O, Bitter T, Takes R, Lee VHF, Saba NF, Makitie AA, et al. Post COVID-19 and long COVID symptoms in otorhinolaryngology-A narrative review.J Clin Med. (2025) 14(2):1–22. doi: 10.3390/jcm1402050613. Megari K, Thomaidou E, Palioura ME, Parasxiakos S, Skoutara A, Stougioude P, et al. Are neurocognitive deficits associated with gastrointestinal symptoms in children due to COVID-19? Int J Dev Neurosci. (2025) 85(1):e70007. doi: 10.1002/ jdn.7000714. Schlegtendal A, Maier C, Stein J, Hopner J, Petersmann A, Drinka D, et al. Post- coronavirus disease 2019-associated symptoms among children and adolescents in the SARS-CoV-2 omicron era. Eur J Pediatr. (2024) 184(1):96. doi: 10.1007/ s00431-024-05919-315. Ford ND, Vahratian A, Pratt CQ, Yousaf AR, Gregory CO, Saydah S. Long COVID prevalence and associated activity limitation in US children. JAMA Pediatr. (2025) 179(4):471–3. doi: 10.1001/jamapediatrics.2024.620616. Bartsch SM, Chin KL, Strych U, John DC, Shah TD, Bottazzi ME, et al. The current and future burden of long COVID in the United States (U.S.). J Infect Dis. (2025) 231(6):1581–90. doi: 10.1093/infdis/jiaf03017. Gross RS, Thaweethai T, Kleinman LC, Snowden JN, Rosenzweig EB, Milner JD, et al. Characterizing long COVID in children and adolescents. JAMA. (2024) 332(14):1174–88. doi: 10.1001/jama.2024.1274718. Ramirez-Toscano Y, Torres-Ibarra L, Carnalla M, Basto-Abreu A, Vidana-Perez D, Colchero MA, et al. Prevalence of post-COVID conditions among Mexican COVID-19 survivors: a nationwide cross-sectional study. BMC Public Health. (2024) 24(1):1729. doi: 10.1186/s12889-024-19274-319. Martinez-Valdez L, Richardson VL, Bautista-Marquez A, Camacho Franco MA, Cruz Cruz V, Hernandez Avila M. Three years of COVID-19 in children that attend the Mexican social security institute’s 1,350 child day-care centers, 2020–2023. Front Pediatr. (2023) 11:1292629. doi: 10.3389/fped.2023.129262920. Ordonez Azuara Y, Gutierrez Herrera RF, Mendez Espinoza E, Alvarez Villalobos NA, Lopez Mata D, de la Cruz de la Cruz C. Association of family typology and dysfunction in families with adolescents from a Mexican population. Aten Primaria. (2020) 52(10):680–9. doi: 10.1016/j.aprim.2020.02.01121. Polo Payares EP, Ardila Hernández AA, Ibáñez Polo DD. Apoyo social y tipología familiar en mujeres diagnosticadas con VIH. Revista Facultad Nacional de Salud Pública. (2021) 39(1):1–13. doi: 10.17533/udea.rfnsp.e34051722. Asadi-Pooya AA, Nemati H, Shahisavandi M, Akbari A, Emami A, Lotfi M, et al. Long COVID in children and adolescents. World J Pediatr. (2021) 17(5):495–9.doi: 10.1007/s12519-021-00457-623. Shamah-Levy T, Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA, et al. Encuesta nacional de salud y nutrición 2020 sobre COVID-19. Resultados Nacionales. (2021): 125–35. Available online at:https://ensanut.insp.mx/encuestas/ensanutcontinua2020/doctos/informes/ ensanutCovid19ResultadosNacionales.pdf (Accessed March 25, 2026)24. RECOVER. RECOVER: Researching COVID to Enhance Recovery. (2025). Available online at: https://recovercovid.org/ (Accessed April 10, 2025).25. Brinkmann F, Diebner HH, Matenar C, Schlegtendal A, Eitner L, Timmesfeld N, et al. Seroconversion rate and socio-economic and ethnic risk factors for SARS-CoV- 2 infection in children in a population-based cohort, Germany, June 2020 to February 2021. Euro Surveill. (2022) 27(37):1–6. doi: 10.2807/1560-7917.ES.2022.27. 37.210102826. Puntoni M, Esposito S, Patrizi L, Palo CM, Deolmi M, Autore G, et al. Impact of age and sex interaction on post-acute sequelae of COVID-19: an Italian cohort study on adults and children. J Clin Med. (2023) 12(8):2924. doi: 10.3390/ jcm1208292427. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. (2022) 12(1):9950. doi: 10.1038/ s41598-022-13495-528. Wu Q, Zhang B, Tong J, Bailey LC, Bunnell HT, Chen J, et al. Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents. eClinicalMed. (2025) 79:102962. doi: 10.1016/j.eclinm. 2024.10296229. Aragón-Nogales R, Miranda-Novales MG. Vacunación contra COVID-19 en niños. Revista Mexicana de Pediatría. (2021) 88(3):89–92. doi: 10.35366/10218730. Lippi G, Sanchis-Gomar F. Mortality of post-COVID-19 condition: 2025 update.Covid. (2025) 5(1):1–11. doi: 10.3390/covid501001131. Bracco J, Ciaschi M, Gasparini L, Marchionni M, Neidhöfer G. The impact of COVID-19 on education in Latin America: long-run implications for poverty and inequality. Rev Income Wealth. (2024) 71(1):19–28. doi: 10.1111/roiw.1268732. Romero-Ibarguengoitia ME, Rodríguez-Torres JF, Garza-Silva A, Rivera-Cavazos A, Morales-Rodriguez DP, Hurtado-Cabrera M, et al. Association of vaccine status, reinfections, and risk factors with long COVID syndrome. Sci Rep. (2024) 14:2817.doi: 10.1038/s41598-024-52925-433. Nicolay B, Gómez-Bravo R, Hutmacher D, Benoy C, Vögele C. Investigating the impact of the number of COVID-19 reinfections, vaccination status, risk factors, and reinfection interval on long COVID symptomatology. Discov Public Health. (2025) 22:443. doi: 10.1186/s12982-025-00787-0Chipol-Ceja et al. 10.3389/fped.2026.1691052Frontiers in Pediatrics 10 frontiersin.org